Calreticulin displays on cancer cell surface (IMAGE)

University of Illinois at Urbana-Champaign, News Bureau

Calreticulin displays on cancer cell surface

Caption

In human breast cancer cells treated with the preclinical drug ErSO (shown), or with doxorubicin, the cellular protein FGD3 causes another protein, calreticulin (in red), to display on the cancer cell surface, attracting and activating immune cells. 

Credit

Micrographs by Junyao Zhu

Usage Restrictions

credit required

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.